Scarica l'app Stockscreener
26.04
1.36%
0.35
Pre-mercato:
25.94
-0.10
-0.38%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PFE Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$25.69
Aprire:
$25.85
Volume 24 ore:
31.75M
Relative Volume:
0.87
Capitalizzazione di mercato:
$148.41B
Reddito:
$63.32B
Utile/perdita netta:
$7.52B
Rapporto P/E:
19.96
EPS:
1.3043
Flusso di cassa netto:
$9.48B
1 W Prestazione:
-0.53%
1M Prestazione:
-1.55%
6M Prestazione:
+0.04%
1 anno Prestazione:
+12.63%
Intervallo 1D:
$25.79
$26.21
Intervallo di 1 settimana:
$25.27
$26.21
Portata 52W:
$23.11
$28.75
Pfizer Inc Stock (PFE) Company Profile
Nome
Pfizer Inc
Settore
Industria
Telefono
(212) 733-2323
Indirizzo
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Compare PFE vs LLY, JNJ, ABBV, MRK, AZN
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
26.04 | 146.42B | 63.32B | 7.52B | 9.48B | 1.3043 |
LLY
Lilly Eli Co
|
1,131.42 | 1.00T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
232.77 | 549.25B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
227.23 | 397.42B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
120.79 | 297.02B | 65.51B | 8.93B | 14.12B | 3.5532 |
AZN
Astrazeneca Plc
|
185.95 | 281.95B | 60.48B | 10.40B | 8.05B | 3.3297 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-02 | Aggiornamento | Argus | Hold → Buy |
| 2026-02-25 | Iniziato | RBC Capital Mkts | Underperform |
| 2026-02-20 | Iniziato | Barclays | Underweight |
| 2026-02-12 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2026-01-07 | Ripresa | UBS | Neutral |
| 2025-12-02 | Ripresa | Citigroup | Neutral |
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Neutral |
| 2024-12-10 | Ripresa | BofA Securities | Neutral |
| 2024-11-15 | Iniziato | Wolfe Research | Underperform |
| 2024-10-25 | Ripresa | Citigroup | Neutral |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-08-07 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | Downgrade | Argus | Buy → Hold |
| 2024-02-23 | Iniziato | Guggenheim | Buy |
| 2024-01-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | Ripresa | UBS | Neutral |
| 2023-10-16 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-17 | Reiterato | JP Morgan | Neutral |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-06-29 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | Iniziato | Jefferies | Hold |
| 2023-02-07 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | Downgrade | UBS | Buy → Neutral |
| 2023-01-17 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-12-13 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-04-06 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-01-05 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-01-03 | Reiterato | Bernstein | Mkt Perform |
| 2021-12-20 | Reiterato | Cowen | Outperform |
| 2021-12-17 | Iniziato | Goldman | Neutral |
| 2021-12-13 | Aggiornamento | UBS | Neutral → Buy |
| 2021-12-09 | Iniziato | Wells Fargo | Overweight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-05-06 | Downgrade | Mizuho | Buy → Neutral |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | Aggiornamento | DZ Bank | Hold → Buy |
| 2020-12-16 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | Ripresa | Goldman | Neutral |
| 2020-11-10 | Ripresa | Bernstein | Mkt Perform |
| 2020-10-12 | Downgrade | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-06-16 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-02-27 | Aggiornamento | Standpoint Research | Hold → Buy |
| 2020-02-06 | Iniziato | Mizuho | Buy |
| 2020-01-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-07-30 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | Ripresa | Morgan Stanley | Overweight |
| 2019-02-20 | Ripresa | Citigroup | Neutral |
| 2019-01-31 | Aggiornamento | Argus | Hold → Buy |
| 2019-01-31 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | Downgrade | UBS | Buy → Neutral |
| 2018-12-11 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-11-01 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
Mostra tutto
Pfizer Inc Borsa (PFE) Ultime notizie
Pfizer-Partnered Obesity Drugmaker Eyes Deals Outside China - Bloomberg.com
Pfizer (PFE) Stock Gains Ground on Once-Monthly Obesity Drug Breakthrough - Blockonomi
3 Dividend Stocks to Buy Hand Over Fist in June - The Motley Fool
Pfizer’s monthly obesity shot has side-effect profile similar to Wegovy - NewsNation
Pfizer working on 1st once-a-month anti-obesity drug - Magzter
What to know about berobenatide, Pfizer’s experimental obesity drug - AOL.com
Pfizer’s Berobenatide GLP-1 Obesity Data Might Change The Case For Investing In Pfizer (PFE) - Yahoo Finance
Can Pfizer's Dividend Survive the Patent Cliff? This $10.5 Billion Cancer Bet Could Hold the Answer. - The Motley Fool
Pfizer Revenue Recovery and Patent Cliff: Analysis as of June 2026News and Statistics - IndexBox
Comirnaty COVID-19 vaccine: what US patients should know - AD HOC NEWS
Pfizer's 6.7% Yield Looks Scary -- but the Dividend Story Is Stronger Than It Seems - Yahoo Finance
Pfizer (PFE) Advances Obesity Therapy with Promising Mid-Stage T - GuruFocus
Pfizer says mid-stage trial data support monthly dosing for GLP-1 therapy - Seeking Alpha
Pfizer targets obesity market with monthly weight-loss injection data - Investing.com
Pfizer Bets on Weight-Loss Drugs to Power Its Next Decade - Bloomberg.com
Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer’s GLP-1 RA Berobenatide - The Joplin Globe
Assessing Pfizer (PFE) Valuation As Shares Recover From A Mixed Recent Performance - Yahoo Finance
Pfizer Options Spot-On: On June 5th, 143.52K Contracts Were Traded, With 2.67 Million Open Interest - Moomoo
Pfizer Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
Pfizer Inc. stock (US7170811035): shares steady ahead of next catalyst as investors focus on valuati - AD HOC NEWS
Pfizer’s integrin β6 ADC advances intravesical therapy for NMIBC - BioWorld News
Pfizer licenses Chai Discovery AI platform for drug discovery - Yahoo Finance
PFIZER INC : Jefferies reaffirms its Buy rating - marketscreener.com
Rx Rundown: Pfizer, Hikma Pharmaceuticals, NewLimit and more - Medical Marketing and Media
Pfizer signs licence agreement with Chai for AI drug discovery - Yahoo Finance
How New Multi‑Tumor Oncology Data At Pfizer (PFE) Has Changed Its Investment Story - simplywall.st
Pfizer gets a jump on Chai's new model, thanks to drug discovery pact - FirstWord Pharma
Diamond Blackfan Anemia Market Unlocking New Revenue Opportunities and Strategic Expansion by 2036 – DelveInsight | Novartis AG, AstraZeneca, Pfizer Inc., Sanofi, Merck KGaA - Barchart.com
Pfizer Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Pfizer Taps Chai Discovery AI To Expand Biologics Pipeline Potential - Yahoo Finance
Why Is Pfizer (PFE) Down 4.5% Since Last Earnings Report? - Yahoo Finance
Pfizer Inc stock (US7170811035): focus on oncology pipeline after Jefferies 2026 appearance - AD HOC NEWS
Pfizer to Leverage Chai Discovery’s AI Platform - Contract Pharma
Chai Discovery Announces License Agreement with Pfizer to Accelerate Drug Discovery with AI - Yahoo Finance
Pfizer Inc. stock (US7170811035): oncology collaboration focus after Jefferies conference update - AD HOC NEWS
Southwest Securities: Innovent Bio (01801) Partners with Pfizer to Accelerate Development of Innovative Oncology Therapies - 富途牛牛
Innovent’s $10.5 billion deal marks new model for China drugmakers - thebambooworks.com
Pfizer Inc. stock (US7170811035): shares steady as investors digest oncology deal news and recent ea - AD HOC NEWS
Pfizer vs Merck: Chasing High Yield vs Higher Returns - 24/7 Wall St.
Bristol Myers vs. Pfizer: Which High‑Yield Dividend Stock Wins Now? - The Globe and Mail
Meet the biotech stock that's trouncing Lilly, Merck, and Pfizer in 2026 - MSN
Meet the Biotech Stock That's Trouncing Lilly, Merck, and Pfizer in 2026 - Yahoo Finance
Opportunities in the Oncology Market: Positioning for the Next Billion-Dollar Catalyst with BioNTech, Vidac Pharma, and Pfizer - news.financial
Pfizer Oncology Data At ASCO 2026 Reshapes Long Term Growth Story - Yahoo Finance
Pfizer lifts 2022 forecast for Covid-19 vaccine sales as profits rise - Digital Journal
ADCs, multispecific antibodies anchor $10B Pfizer-Innovent deal - BioWorld News
Is Pfizer Inc. (PFE) Expanding Its Cancer Pipeline Through a Landmark Innovent Partnership? - Insider Monkey
Pfizer's Obesity and Oncology Pipeline Sets Up a Catalyst-Rich 2026 - The Globe and Mail
Why Pfizer’s Current Price May Be Too Cheap to Ignore - Yahoo Finance
Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Stock - Yahoo Finance Singapore
Pfizer’s ASCO 2026 Cancer Results Test Oncology Focus And Valuation Story - simplywall.st
Pfizer Inc Azioni (PFE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Pfizer Inc Azioni (PFE) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| LANKLER DOUGLAS M | Executive Vice President |
Feb 25 '26 |
Option Exercise |
33.82 |
122,907 |
4,156,715 |
282,186 |
| DAMICO JENNIFER B. | SVP & Controller |
Feb 25 '26 |
Option Exercise |
33.82 |
17,558 |
593,812 |
29,744 |
| BOURLA ALBERT | Chairman & CEO |
Feb 25 '26 |
Option Exercise |
33.82 |
491,626 |
16,626,791 |
864,215 |
| Fonseca Lidia | Executive Vice President |
Feb 25 '26 |
Option Exercise |
33.82 |
56,888 |
1,923,952 |
101,579 |
| McDermott Michael | Executive Vice President |
Feb 25 '26 |
Option Exercise |
33.82 |
37,925 |
1,282,624 |
114,534 |
0.02%
1.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):